Navigating New Treatment Options and Balancing Toxicities in Gastric and GEJ Cancer
Key Points
- The current standard of care in upper GI adenocarcinoma is perioperative durvalumab plus FLOT regimen with surgery, with an additional year of durvalumab.
- A significant development in treatment of GI cancers is the approval of zanidatamab in combination with chemotherapy for first-line treatment of adults with HER2-positive disease.
- Managing toxicities such as nausea is a critical aspect of treatment; the key is to ensure patients are educated on what to expect and when.
- In later stages of treatment, it’s important to be “attentive to the balance of toxicity and efficacy and preserving quality of life.”
Advances in research have significantly evolved the treatment algorithm for esophageal gastroesophageal junction (GEJ) and gastric adenocarcinoma. On the Oncology Brothers podcast, co-hosts Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, spoke with Samuel J. Klempner, MD, of Massachusetts General Hospital, about his experiences as a gastrointestinal medical oncologist.
Along with therapeutic strategies — from early-disease systemic treatment to metastatic treatment — the experts also explored the critical role of biomarkers in guiding decisions and managing toxicities.
Durvalumab Plus FLOT
For patients with early resectable disease, the current standard of care in upper GI adenocarcinoma is perioperative durvalumab plus FLOT regimen with surgery, with an additional year of durvalumab. According to Dr. Klempner, this course has improved event-free survival and overall survival. It marks a departure from previous strategies in which treatment focused solely on local therapy. That evolution “has placed intensive systemic therapy with immunotherapy in a perioperative setting at the forefront,” he said.
In the MATTERHORN trial, durvalumab plus FLOT exhibited a manageable safety profile, which is critical given the wide range of patients affected by the disease. It is, however, an “intensive regimen,” Dr. Klempner said. “We put our patients through a lot to get them a chance at a cure, but this is what the data suggest is required.”
For patients who are not surgical candidates after definitive concurrent chemotherapy and are experiencing residual disease, the course isn’t as clearly defined. “It’s a tough spot,” said Dr. Klempner. Currently, there are no data to support continuation checkpoint inhibitors, he said, adding that he advises against using PDL1 scores as a marker for immunotherapy given the heterogeneity around scoring. “I don’t think we have adequate evidence to withhold therapy,” he said. “In a curative setting, I’m conservative and stay within what the data suggest, because we want to do everything we can” to improve outcomes.
Checking MSI-H
Dr. Klempner does advise checking for Microsatellite instability-high (MSI-H), which occurs in nearly 30% of individuals in their 70s and 80s. “We check every single gastric biopsy,” he said. “Pathologists don’t always know whether it’s a T1 tumor or a metastatic disease, and so they test MMR for everyone. I think it’s the right thing, because these are patients that do very well both prognostically and with neoadjuvant immunotherapy.”
For those who are non-operative and non-metastatic, immunotherapy usually continues for around 12 months, with surveillance endoscopies occurring every three months, then more sporadically. “The recurrence risk, if it’s going to happen, is on the earlier side
for persistent local disease,” said Dr. Klempner. “But these patients often do really well.”
In patients with metastatic disease, biomarkers — including HER2 status, PD-L1 score, and Claudin 18.2 — are leveraged to guide treatment decisions.
Zanidatamab Plus Chemotherapy
One of the most significant developments of 2026 is the approval of zanubrutinib in combination with chemotherapy for first-line treatment of adults with HER2-positive disease. The drug, according to Dr. Klempner, can pave the way to “more effective biologic targeting of HER2 with its biparatropic mechanism.” In a phase 3 trial, the triplet regimen of zanidatamab, chemotherapy, and tislelizumab demonstrated an improved survival rate compared with traditional trastuzumab and chemotherapy. “It was a very clean comparison and a very clear win,” he said, noting that he plans to offer the triplet regimen to his patients.
Managing Toxicities
One of the biggest concerns in treating GI cancers is toxicities. The key to management, according to Dr. Klempner, is educating patients on what to expect. Nausea is common, possibly during the first infusion, but tends to subside over subsequent cycles. “As long as there are no surprises, we can navigate most toxicities,” he said. “Patients understand that the drug is active and has improved survival, and they’ll usually take that trade.”
Gastritis can also occur in patients taking zolbetuximab and can be “insidious and subacute.” For those experiencing persistent GI upset and nausea after five days, he recommended scoping to determine whether active gastritis is present. If that’s the case, it should be managed “conservatively,” avoiding high-dose steroids. Peripheral edema can also occur, and should be managed prudently through methods like dose interruptions and diuretics.
When disease has progressed, it’s important to be “very attentive to the balance of toxicity and efficacy and preserving quality of life,” said Dr. Klempner. “This is a palliative setting.” Depending on the disease state and patient, it may be possible to alternate treatments to ensure longer intervals between appointments. “Patients appreciate that,” he said.
Looking ahead, the experts expect more data to emerge in the treatment of gastric and GEJ cancers that will further shift the paradigm away from traditional chemotherapy, including more in the way of antibody-drug conjugates.